Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk

Eur Heart J. 2020 Oct 7;41(38):3743-3749. doi: 10.1093/eurheartj/ehaa671.


Aims: To validate the set of clinical and biochemical criteria proposed by consensus by the Academic Research Consortium (ARC) for High Bleeding Risk (HBR) for the identification of HBR patients. These criteria were categorized into major and minor, if expected to carry in isolation, respectively, ≥4% and <4% Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding risk within 1-year after percutaneous coronary intervention (PCI). High bleeding risk patients are those meeting at least 1 major or 2 minor criteria.

Methods and results: All patients undergoing PCI at Bern University Hospital, between February 2009 and September 2018 were prospectively entered into the Bern PCI Registry (NCT02241291). Age, haemoglobin, platelet count, creatinine, and use of oral anticoagulation were prospectively collected, while the remaining HBR criteria except for planned surgery were retrospectively adjudicated. A total of 16 580 participants with complete ARC-HBR criteria were included. After assigning 1 point to each major and 0.5 point to each minor criterion, we observed for every 0.5 score increase a step-wise augmentation of BARC 3 or 5 bleeding rates at 1 year ranging from 1.90% among patients fulfilling no criterion, through 4.01%, 5.98%, 7.42%, 8.60%, 12.21%, 12.29%, and 17.64%. All major and five out of six minor criteria, conferred in isolation a risk for BARC 3 or 5 bleeding at 1 year exceeding 4% at the upper limit of the 95% confidence intervals.

Conclusion: All major and the majority of minor ARC-HBR criteria identify in isolation patients at HBR.

Keywords: Academic Research Consortium; Bleeding; Percutaneous coronary intervention; Validation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hemorrhage / chemically induced
  • Humans
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors
  • Retrospective Studies
  • Risk Factors


  • Platelet Aggregation Inhibitors